1) The Chairman discussed Biocon's focus on developing affordable biopharmaceuticals to make healthcare more accessible globally through five growth verticals.
2) These verticals include small molecules, biosimilars, branded formulations, novel molecules, and integrated research services. Biosimilars and insulin formulations are seen as major growth opportunities.
3) Biocon is augmenting manufacturing, R&D, and marketing capabilities to pursue strong sustainable growth through a new facility in Malaysia and an R&D center in Bangalore. Clinical trials show promise for biosimilar molecules in development.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company based in India. It discusses Biocon's vision, business structure, product portfolio including branded formulations in India, research and development pipeline including potential new molecules and biosimilars. It also outlines strategic partnerships with Pfizer and Mylan to commercialize biosimilar insulins and monoclonal antibodies globally. Financial highlights show strong revenue and profit growth over the past years and in the first half of fiscal year 2012.
The document provides results and highlights from Biocon for fiscal year 2012. It discusses Biocon's 16% revenue growth to Rs. 2,148 crores and EBITDA and PAT margins of 27% and 16% respectively. It outlines Biocon's research and development efforts including positive results from a phase 3 clinical trial of Itolizumab for psoriasis. It also discusses Biocon's partnerships with Mylan for biosimilar monoclonal antibodies and its biosimilars portfolio including insulin products in clinical trials. The financial highlights section shows Q4 and full year 2012 results.
Biocon Q1 FY13 Results Presentation July 2012Biocon
Biocon reported strong financial results for the first quarter of fiscal year 2013, with revenues of 593 Crores and earnings before interest, taxes, depreciation, and amortization (EBITDA) of 139 Crores. All of Biocon's business verticals performed well, with the biopharma business growing 23% year-over-year and the branded formulations business growing 52% year-over-year. Research and development spending increased 75% year-over-year to support clinical trials and product development. Biocon is in discussions for licensing several research programs and expects to finalize agreements going forward.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company. It discusses Biocon's vision, business structure, product portfolio including branded formulations in India where it has the number 1 or 2 market share for several drugs. The presentation outlines Biocon's research and development efforts including its pipeline of novel molecules and biologics in diabetes, oncology and immunology. Key pipeline programs discussed are Itolizumab in Phase 3 for rheumatoid arthritis, IN-105 for oral insulin, and partnerships for strategic alliances.
Q1FY14: Biocon Delivers a Healthy Growth of 22% driven by strong traction in ...Biocon
Biocon delivered 22% revenue growth in Q1 FY14 driven by strong performance in its biopharma business. Revenues were ₹723 crores with EBITDA of ₹175 crores and PAT of ₹94 crores. The company's insulin business continues to grow due to an increased geographic footprint in emerging markets. Research services also grew at 26% due to increased demand for integrated services. Biocon plans to launch its second novel biologic, Alzumab, for the treatment of psoriasis in India in the current fiscal year.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company. In 3 sentences:
Biocon has a portfolio approach across small molecules, biosimilars, branded formulations and novel molecules. It has strategic partnerships for commercialization and research. Financial highlights showed steady revenue and profit growth over 2008-2011, with revenues reaching $402 million and net profit of $74 million in fiscal year 2011.
Psoriasis is a chronic skin condition caused by genetic and environmental factors. It is characterized by red, scaly patches on the skin. While there is no way to prevent psoriasis, patients can help prevent flare ups by maintaining a healthy lifestyle and avoiding triggers. Treatments range from topical creams and drugs to phototherapy and biological treatments. Biological treatments are very effective but also expensive, while other traditional systems like homeopathy and ayurveda may also help if the treatment is genuine.
1) The Chairman discussed Biocon's focus on developing affordable biopharmaceuticals to make healthcare more accessible globally through five growth verticals.
2) These verticals include small molecules, biosimilars, branded formulations, novel molecules, and integrated research services. Biosimilars and insulin formulations are seen as major growth opportunities.
3) Biocon is augmenting manufacturing, R&D, and marketing capabilities to pursue strong sustainable growth through a new facility in Malaysia and an R&D center in Bangalore. Clinical trials show promise for biosimilar molecules in development.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company based in India. It discusses Biocon's vision, business structure, product portfolio including branded formulations in India, research and development pipeline including potential new molecules and biosimilars. It also outlines strategic partnerships with Pfizer and Mylan to commercialize biosimilar insulins and monoclonal antibodies globally. Financial highlights show strong revenue and profit growth over the past years and in the first half of fiscal year 2012.
The document provides results and highlights from Biocon for fiscal year 2012. It discusses Biocon's 16% revenue growth to Rs. 2,148 crores and EBITDA and PAT margins of 27% and 16% respectively. It outlines Biocon's research and development efforts including positive results from a phase 3 clinical trial of Itolizumab for psoriasis. It also discusses Biocon's partnerships with Mylan for biosimilar monoclonal antibodies and its biosimilars portfolio including insulin products in clinical trials. The financial highlights section shows Q4 and full year 2012 results.
Biocon Q1 FY13 Results Presentation July 2012Biocon
Biocon reported strong financial results for the first quarter of fiscal year 2013, with revenues of 593 Crores and earnings before interest, taxes, depreciation, and amortization (EBITDA) of 139 Crores. All of Biocon's business verticals performed well, with the biopharma business growing 23% year-over-year and the branded formulations business growing 52% year-over-year. Research and development spending increased 75% year-over-year to support clinical trials and product development. Biocon is in discussions for licensing several research programs and expects to finalize agreements going forward.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company. It discusses Biocon's vision, business structure, product portfolio including branded formulations in India where it has the number 1 or 2 market share for several drugs. The presentation outlines Biocon's research and development efforts including its pipeline of novel molecules and biologics in diabetes, oncology and immunology. Key pipeline programs discussed are Itolizumab in Phase 3 for rheumatoid arthritis, IN-105 for oral insulin, and partnerships for strategic alliances.
Q1FY14: Biocon Delivers a Healthy Growth of 22% driven by strong traction in ...Biocon
Biocon delivered 22% revenue growth in Q1 FY14 driven by strong performance in its biopharma business. Revenues were ₹723 crores with EBITDA of ₹175 crores and PAT of ₹94 crores. The company's insulin business continues to grow due to an increased geographic footprint in emerging markets. Research services also grew at 26% due to increased demand for integrated services. Biocon plans to launch its second novel biologic, Alzumab, for the treatment of psoriasis in India in the current fiscal year.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company. In 3 sentences:
Biocon has a portfolio approach across small molecules, biosimilars, branded formulations and novel molecules. It has strategic partnerships for commercialization and research. Financial highlights showed steady revenue and profit growth over 2008-2011, with revenues reaching $402 million and net profit of $74 million in fiscal year 2011.
Psoriasis is a chronic skin condition caused by genetic and environmental factors. It is characterized by red, scaly patches on the skin. While there is no way to prevent psoriasis, patients can help prevent flare ups by maintaining a healthy lifestyle and avoiding triggers. Treatments range from topical creams and drugs to phototherapy and biological treatments. Biological treatments are very effective but also expensive, while other traditional systems like homeopathy and ayurveda may also help if the treatment is genuine.
CMD Kiran Mazumdar Shaw Speech at Biocon's 38th Annual General Meeting 2016 Biocon
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
1) Alzumab, an antibody developed by Biocon Ltd to treat psoriasis, showed promising results in clinical trials, effectively treating a patient's psoriasis within 8 weeks.
2) Alzumab works through the Th17 immune pathway and has the potential to treat over 100 autoimmune diseases. It was launched in India to treat psoriasis in August 2013.
3) Biocon's development of Alzumab was a breakthrough for the company and Indian innovation, as it was developed through a decade-long process and may establish credibility for Indian clinical research.
Este documento presenta los ganadores de los trabajos de Navidad realizados por los alumnos de la Asociación de Madres y Padres “San Vicente de Paul” del Colegio San José Infantil Primaria E.S.O Bachiller. Se enumeran los ganadores y segundos premios de cada categoría: Infantil, Primaria 1, Primaria 2 y E.S.O Bachiller.
Biocon investor conference call for the nine months ended 31st December 2011 ...Biocon
This transcript summarizes the Q3 FY12 earnings conference call of Biocon Limited.
[1] Biocon's Chairman and Managing Director Kiran Mazumdar-Shaw discussed the company's performance for the first three quarters of FY12. Revenue grew 15% excluding licensing income, while profits grew nearly 30%. However, licensing income declined sharply from the previous year, resulting in flat overall earnings.
[2] Mazumdar-Shaw highlighted five key growth verticals for Biocon going forward: small molecules, biosimilars, branded formulations, novel molecules, and research services. She expressed confidence in delivering high double-digit growth over the next 5 years through these verticals.
India's first Int'l Conference on Best Practices in Pharma Microbiology Biocon
This is the first time that Pharmig, an international Pharmaceutical Microbiology think tank based out of the UK is organizing a conference on the "Best Practices in Pharma Microbiology" for the first time in India. You can register
by sending an email to maxine@pharmig.org.uk. For booking a seat for the conference, please visit: http://bit.ly/1J4gtLh
The document provides tips for quitting tobacco use. It recommends making a plan to quit on a specific date and getting support. Withdrawal symptoms like cravings can occur for weeks after quitting. Nicotine replacements can help with cravings. Tips include avoiding places one used tobacco, keeping busy, and remembering the health benefits of quitting like reduced risk of heart attack and improved circulation and taste. It encourages trying again if the first attempt at quitting fails.
The document provides an overview of Biocon's business including:
1) Biocon is an emerging global biopharmaceutical company focused on developing affordable therapies for chronic diseases like diabetes and cancer.
2) In FY2012, Biocon saw 16% revenue growth and a 27% EBITDA margin, initiated several clinical trials, and formed new strategic partnerships.
3) Biocon has a diversified portfolio spanning small molecules, branded formulations, biosimilars, and research services.
The document describes a photography project at St Luke the Evangelist Primary School aimed at building community partnerships through creative self-expression. Professional development workshops were provided for students, staff, and parents to learn photography skills. Families then participated in activities together to take photos reflecting their values. The photos will be displayed in an art piece representing the school community's identity. The project enhances curriculum learning and relationships by encouraging shared skills and perspectives through photography.
Canara Bank, Biocon Foundation and OTTET join hands to strengthen Healthcare ...Biocon
Canara Bank, Biocon Foundation, and OTTET have formed a public-private partnership to strengthen healthcare delivery in Odisha, India. Under this partnership, Biocon Foundation and OTTET will set up electronic diagnostic facilities and e-Health centers at primary health centers in Odisha managed by local entrepreneurs provided financial assistance from Canara Bank. This model aims to improve access to quality healthcare for rural communities by providing diagnostics, telemedicine consultations, and maintaining electronic health records.
Integrative Research In Oncology On May 15, 2012Biocon
On May 15, 2012, Biocon held a symposium on integrative research in oncology at their research center. Key speakers at the event included the director of the Koch Institute for Integrative Cancer Research, the president of R&D at Biocon, and professors from Harvard Medical School. Panel discussions were held on topics such as translational research with marketed oncology products and personalized cancer treatment approaches.
Walk-in Drive at Indore, Madhya Pradesh on Dec 11, 2016 (9AM-2PM)Biocon
This document announces job openings for several positions at a location in Bangalore, India. It provides requirements for Fill Finish Production, Insulin Production, Engineering & Maintenance, and Instrumentation roles. All positions require experience in a pharmaceutical or healthcare setting and working in shifts. Candidates should bring documentation to an interview at a hotel in Indore, Madhya Pradesh.
Walk-in Drive at Aurangabad, Maharashtra on Oct 23, 2016Biocon
Walk-in drive at Aurangabad for positions in Fill finish Production, Fill finish Packing, Engineering & Maintenance, Instrumentation, Insulin Production and Packing inspection.
Date: Oct 23, Sunday (9AM-2PM)
Venue: The Salt, MGM-Sports Club & Stadium, Behind MGM Hospital, N-6 CIDCO, MGM Campus, Aurangabad, 431003
#Job #Recruitment #Biotechnology #Hiring
Biocon Walk in Interviews at Hyderabad on May 22, 2016Biocon
This document provides information about a walk-in interview being held by Biocon Limited in Hyderabad for various positions at their API, Biosimilars, and Injectable facilities in Bangalore. The walk-in will take place on May 22nd, 2016 from 9:00AM to 2:00PM at the Hotel Sree Krishnaa Grand in Hyderabad. Candidates should bring the required documents and register online. A number of positions are listed along with their required qualifications and experience.
Biocon organizing walk-in interviews at VishakhapatnamBiocon
Biocon Walk In at Vishakhapatnam
Venue: -
Integral Institute of Advanced Management (IIAM)
Plot Not 10, Sector 7, MVP Colony, Visakhapatnam - 530 017.
Landmark: Near to CBI Office
Date: Sunday, 22nd May 2016. Time: 9:00AM- 02:00PM
Biocon organizing walk-in interviews at Don Bosco College, Margao, GoaBiocon
Biocon Limited is India's premier biopharma company focused on delivering affordable healthcare globally. It has evolved into an emerging global enterprise serving over 100 partners and customers in 100+ countries. Biocon is ranked #6 among the top 20 global biotech employers by Science Magazine in 2013.
Biocon is looking for experienced professionals for their injectable facilities in Bangalore. Positions include Junior Executive/Executive/Senior Executive/Assistant Manager in Production, Junior Executive/Executive/Senior Executive in Engineering & Maintenance, and Executive/Senior Executive in Validation & Compliance. Candidates should bring documents including photos, CVs, educational and work experience certificates to the walk-in on December 13, 2015 in Margao
Biocon Walkin Interviews Hyderabad 29th November 2015Biocon
All available positions are Bangalore based. This document contains details of the Walkin Interviews scheduled to be held in Hyderabad on the 29th of November, Sunday.Refer this document for available positions and mandatory documents including venue details. Interested candidates can register themselves by clicking here: http://bit.ly/1lNUQGG
CMD Kiran Mazumdar Shaw Speech at Biocon's 38th Annual General Meeting 2016 Biocon
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
1) Alzumab, an antibody developed by Biocon Ltd to treat psoriasis, showed promising results in clinical trials, effectively treating a patient's psoriasis within 8 weeks.
2) Alzumab works through the Th17 immune pathway and has the potential to treat over 100 autoimmune diseases. It was launched in India to treat psoriasis in August 2013.
3) Biocon's development of Alzumab was a breakthrough for the company and Indian innovation, as it was developed through a decade-long process and may establish credibility for Indian clinical research.
Este documento presenta los ganadores de los trabajos de Navidad realizados por los alumnos de la Asociación de Madres y Padres “San Vicente de Paul” del Colegio San José Infantil Primaria E.S.O Bachiller. Se enumeran los ganadores y segundos premios de cada categoría: Infantil, Primaria 1, Primaria 2 y E.S.O Bachiller.
Biocon investor conference call for the nine months ended 31st December 2011 ...Biocon
This transcript summarizes the Q3 FY12 earnings conference call of Biocon Limited.
[1] Biocon's Chairman and Managing Director Kiran Mazumdar-Shaw discussed the company's performance for the first three quarters of FY12. Revenue grew 15% excluding licensing income, while profits grew nearly 30%. However, licensing income declined sharply from the previous year, resulting in flat overall earnings.
[2] Mazumdar-Shaw highlighted five key growth verticals for Biocon going forward: small molecules, biosimilars, branded formulations, novel molecules, and research services. She expressed confidence in delivering high double-digit growth over the next 5 years through these verticals.
India's first Int'l Conference on Best Practices in Pharma Microbiology Biocon
This is the first time that Pharmig, an international Pharmaceutical Microbiology think tank based out of the UK is organizing a conference on the "Best Practices in Pharma Microbiology" for the first time in India. You can register
by sending an email to maxine@pharmig.org.uk. For booking a seat for the conference, please visit: http://bit.ly/1J4gtLh
The document provides tips for quitting tobacco use. It recommends making a plan to quit on a specific date and getting support. Withdrawal symptoms like cravings can occur for weeks after quitting. Nicotine replacements can help with cravings. Tips include avoiding places one used tobacco, keeping busy, and remembering the health benefits of quitting like reduced risk of heart attack and improved circulation and taste. It encourages trying again if the first attempt at quitting fails.
The document provides an overview of Biocon's business including:
1) Biocon is an emerging global biopharmaceutical company focused on developing affordable therapies for chronic diseases like diabetes and cancer.
2) In FY2012, Biocon saw 16% revenue growth and a 27% EBITDA margin, initiated several clinical trials, and formed new strategic partnerships.
3) Biocon has a diversified portfolio spanning small molecules, branded formulations, biosimilars, and research services.
The document describes a photography project at St Luke the Evangelist Primary School aimed at building community partnerships through creative self-expression. Professional development workshops were provided for students, staff, and parents to learn photography skills. Families then participated in activities together to take photos reflecting their values. The photos will be displayed in an art piece representing the school community's identity. The project enhances curriculum learning and relationships by encouraging shared skills and perspectives through photography.
Canara Bank, Biocon Foundation and OTTET join hands to strengthen Healthcare ...Biocon
Canara Bank, Biocon Foundation, and OTTET have formed a public-private partnership to strengthen healthcare delivery in Odisha, India. Under this partnership, Biocon Foundation and OTTET will set up electronic diagnostic facilities and e-Health centers at primary health centers in Odisha managed by local entrepreneurs provided financial assistance from Canara Bank. This model aims to improve access to quality healthcare for rural communities by providing diagnostics, telemedicine consultations, and maintaining electronic health records.
Integrative Research In Oncology On May 15, 2012Biocon
On May 15, 2012, Biocon held a symposium on integrative research in oncology at their research center. Key speakers at the event included the director of the Koch Institute for Integrative Cancer Research, the president of R&D at Biocon, and professors from Harvard Medical School. Panel discussions were held on topics such as translational research with marketed oncology products and personalized cancer treatment approaches.
Walk-in Drive at Indore, Madhya Pradesh on Dec 11, 2016 (9AM-2PM)Biocon
This document announces job openings for several positions at a location in Bangalore, India. It provides requirements for Fill Finish Production, Insulin Production, Engineering & Maintenance, and Instrumentation roles. All positions require experience in a pharmaceutical or healthcare setting and working in shifts. Candidates should bring documentation to an interview at a hotel in Indore, Madhya Pradesh.
Walk-in Drive at Aurangabad, Maharashtra on Oct 23, 2016Biocon
Walk-in drive at Aurangabad for positions in Fill finish Production, Fill finish Packing, Engineering & Maintenance, Instrumentation, Insulin Production and Packing inspection.
Date: Oct 23, Sunday (9AM-2PM)
Venue: The Salt, MGM-Sports Club & Stadium, Behind MGM Hospital, N-6 CIDCO, MGM Campus, Aurangabad, 431003
#Job #Recruitment #Biotechnology #Hiring
Biocon Walk in Interviews at Hyderabad on May 22, 2016Biocon
This document provides information about a walk-in interview being held by Biocon Limited in Hyderabad for various positions at their API, Biosimilars, and Injectable facilities in Bangalore. The walk-in will take place on May 22nd, 2016 from 9:00AM to 2:00PM at the Hotel Sree Krishnaa Grand in Hyderabad. Candidates should bring the required documents and register online. A number of positions are listed along with their required qualifications and experience.
Biocon organizing walk-in interviews at VishakhapatnamBiocon
Biocon Walk In at Vishakhapatnam
Venue: -
Integral Institute of Advanced Management (IIAM)
Plot Not 10, Sector 7, MVP Colony, Visakhapatnam - 530 017.
Landmark: Near to CBI Office
Date: Sunday, 22nd May 2016. Time: 9:00AM- 02:00PM
Biocon organizing walk-in interviews at Don Bosco College, Margao, GoaBiocon
Biocon Limited is India's premier biopharma company focused on delivering affordable healthcare globally. It has evolved into an emerging global enterprise serving over 100 partners and customers in 100+ countries. Biocon is ranked #6 among the top 20 global biotech employers by Science Magazine in 2013.
Biocon is looking for experienced professionals for their injectable facilities in Bangalore. Positions include Junior Executive/Executive/Senior Executive/Assistant Manager in Production, Junior Executive/Executive/Senior Executive in Engineering & Maintenance, and Executive/Senior Executive in Validation & Compliance. Candidates should bring documents including photos, CVs, educational and work experience certificates to the walk-in on December 13, 2015 in Margao
Biocon Walkin Interviews Hyderabad 29th November 2015Biocon
All available positions are Bangalore based. This document contains details of the Walkin Interviews scheduled to be held in Hyderabad on the 29th of November, Sunday.Refer this document for available positions and mandatory documents including venue details. Interested candidates can register themselves by clicking here: http://bit.ly/1lNUQGG
New Candidate Registration & Application Process: Navigation from Biocon.comBiocon
To apply for a job at Biocon Ltd., candidates must first create a profile by registering with a username and password. They can then search for suitable jobs, select one, and complete the application in the applicant cockpit. Alternatively, candidates can log in if they already have a profile and search for jobs or continue building their profile before applying. The registration and application process is designed to help candidates create a profile and apply for jobs on the corporate website.
Biocon Bio Waste Disposal Company Statement Biocon
This is the official company statement regarding the trucks carrying waste from Biocon to Terra Firma for disposal as per Pollution Control Board Norms
This document provides details about the available positions for the Biocon Walk In Interviews scheduled to be held on the 28th of June, 2015. Candidates who are unable to attend the Walk In Interviews, are required to register
themselves on the careers page: http://bit.ly/1TRkJ53
Biocon provides an investor presentation summarizing its business segments and financial performance. It operates in small molecules, biosimilars, branded formulations, research services, and novel molecules. Revenues have grown from $318 million in FY10 to $487 million in FY14. In Q1 FY15, revenues were $124 million. Biosimilars and research services represent key growth opportunities, while it continues developing a pipeline of novel molecules.
Indeed, we have changed the paradigm. Take a look at how we performed in the past year and what were the major developments of the past year. Also, gain an understanding of how we intend to take Biocon to the next level.
Biocon is India's premier biopharma company focused on delivering affordable healthcare globally. It has facilities in Bangalore looking to hire skilled professionals. Positions include production roles in MAbs, fill finish, fermentation, insulin and GPP requiring diplomas or degrees in engineering, chemistry or biotechnology with relevant experience. Other roles include instrumentation, R&D and engineering/maintenance. Candidates should bring documents to a walk-in on November 9th between 9am-4pm or apply online.
World Polio Day is observed annually on October 24th to commemorate the birth of Dr. Jonas Salk, who developed the first polio vaccine. Polio is a highly infectious disease that primarily affects children under 5 and can cause paralysis. The number of polio cases has declined over 99% since 1988 due to a global effort to eradicate the disease through vaccination. India was once considered highly polio-affected but has been polio-free for two years due to a robust vaccination program. However, the risk of polio persists until Pakistan and Bangladesh are also polio-free.
This document discusses avoiding heart attacks and strokes by protecting oneself. It describes several heart conditions including heart failure, which occurs when the heart cannot pump enough blood due to damage from prior heart attacks or other causes. Congenital heart disease refers to defects present at birth, while rheumatic heart disease results from untreated strep throat and damages heart valves over time. Preventing rheumatic fever through prompt antibiotic treatment of strep throat is the best way to avoid rheumatic heart disease.
What are the signs of stroke and what should you doBiocon
Strokes can occur suddenly and cause weakness or numbness on one side of the body, confusion, vision problems, or severe headaches. If someone shows stroke symptoms, call for emergency help immediately. Doctors use scans to diagnose the type of stroke and treat it with medicines to reduce symptoms and prevent future strokes. Rehabilitation after a stroke helps patients regain abilities and adjust to disabilities through exercises and therapies. Adopting a healthy lifestyle and strictly following medical treatment can help prevent additional strokes.
What are the signs of a heart attack and what should you doBiocon
Heart attacks and strokes can strike suddenly and be fatal if assistance is not sought immediately. The document outlines signs of heart attacks and strokes and advises that if any signs are detected, emergency medical help should be contacted without delay. Treatment options are described that may help restore blood flow and minimize damage, but quick action is critical to survival. Lifestyle changes after the event can also help prevent future attacks.
🔥🔥🔥🔥🔥🔥🔥🔥🔥
إضغ بين إيديكم من أقوى الملازم التي صممتها
ملزمة تشريح الجهاز الهيكلي (نظري 3)
💀💀💀💀💀💀💀💀💀💀
تتميز هذهِ الملزمة بعِدة مُميزات :
1- مُترجمة ترجمة تُناسب جميع المستويات
2- تحتوي على 78 رسم توضيحي لكل كلمة موجودة بالملزمة (لكل كلمة !!!!)
#فهم_ماكو_درخ
3- دقة الكتابة والصور عالية جداً جداً جداً
4- هُنالك بعض المعلومات تم توضيحها بشكل تفصيلي جداً (تُعتبر لدى الطالب أو الطالبة بإنها معلومات مُبهمة ومع ذلك تم توضيح هذهِ المعلومات المُبهمة بشكل تفصيلي جداً
5- الملزمة تشرح نفسها ب نفسها بس تكلك تعال اقراني
6- تحتوي الملزمة في اول سلايد على خارطة تتضمن جميع تفرُعات معلومات الجهاز الهيكلي المذكورة في هذهِ الملزمة
واخيراً هذهِ الملزمة حلالٌ عليكم وإتمنى منكم إن تدعولي بالخير والصحة والعافية فقط
كل التوفيق زملائي وزميلاتي ، زميلكم محمد الذهبي 💊💊
🔥🔥🔥🔥🔥🔥🔥🔥🔥
Elevate Your Nonprofit's Online Presence_ A Guide to Effective SEO Strategies...TechSoup
Whether you're new to SEO or looking to refine your existing strategies, this webinar will provide you with actionable insights and practical tips to elevate your nonprofit's online presence.
Temple of Asclepius in Thrace. Excavation resultsKrassimira Luka
The temple and the sanctuary around were dedicated to Asklepios Zmidrenus. This name has been known since 1875 when an inscription dedicated to him was discovered in Rome. The inscription is dated in 227 AD and was left by soldiers originating from the city of Philippopolis (modern Plovdiv).
How to Setup Default Value for a Field in Odoo 17Celine George
In Odoo, we can set a default value for a field during the creation of a record for a model. We have many methods in odoo for setting a default value to the field.
How to Manage Reception Report in Odoo 17Celine George
A business may deal with both sales and purchases occasionally. They buy things from vendors and then sell them to their customers. Such dealings can be confusing at times. Because multiple clients may inquire about the same product at the same time, after purchasing those products, customers must be assigned to them. Odoo has a tool called Reception Report that can be used to complete this assignment. By enabling this, a reception report comes automatically after confirming a receipt, from which we can assign products to orders.
1. Dr. Abdul Kalam’s Letter to Every Indian
Why is the media here so negative?
Why are we in India so embarrassed to recognize our own strengths, our achievements?
We are such a Great NATION.
We have so many amazing success stories but we refuse to acknowledge them. Why?
We are the first in milk production.
We are number one in Remote sensing satellites.
We are the second largest producer of wheat.
We are the second largest producer of rice.
Look at Dr. Sudarshan , he has transferred the tribal village into a self-sustaining, self-driving unit..
There are millions of such achievements but our media is only obsessed in the bad news and
failures and disasters.
I was in Tel Aviv once and I was reading the Israeli newspaper. It was the day after a lot of attacks
and bombardments and deaths had taken place. The Hamas had struck. But the front page of the
newspaper had the picture of a Jewish gentleman who in five years had transformed his desert into
an orchid and a granary. It was this inspiring picture that everyone woke up to. The gory details of
killings, bombardments, deaths, were inside in the newspaper, buried among other news.
In India we only read about death, sickness, terrorism, crime.
Why are we so NEGATIVE?
2. Another question: Why are we, as a nation so obsessed with foreign things?
We want foreign T.Vs, We want foreign shirts. We want foreign technology. Why this obsession with
everything imported.
Do we not realize that self-respect comes with self-reliance?
I was in Hyderabad giving this lecture, when a 14 year old girl asked me for my autograph. I asked
her what her goal in life is..
She replied: I want to live in a developed India.
For her, you and I will have to build this developed India. You must proclaim. India is not an under-
developed nation; it is a highly developed nation.
YOU say that our government is inefficient.
YOU say that our laws are too old.
YOU say that the municipality does not pick up the garbage.
Y OU say that the phones don't work, the railways are a joke. The airline is the worst in the world,
mails never reach their destination.
YOU say that our country has been fed to the dogs and is the absolute pits.
YOU say, say and say…..
What do YOU do about it?
3. Take a person on his way to Singapore.
Give him a name - 'YOURS'. Give him a face - 'YOURS'. YOU walk out of the airport and you are at
your International best.
In Singapore you don't throw cigarette butts on the roads or eat in the stores.
YOU are as proud of their Underground links as they are.. You pay $5 (approx. Rs.. 60) to drive
through Orchard Road (equivalent of Mahim Causeway or Pedder Road) between 5 PM and 8 PM.
YOU come back to the parking lot to punch your parking ticket if you have over stayed in a
restaurant or a shopping mall irrespective of your status identity…
In Singapore you don't say anything, DO YOU?
YOU wouldn't dare to eat in public during Ramadan, in Dubai ..
YOU would not dare to go out without your head covered in Jeddah.
YOU would not dare to buy an employee of the telephone exchange in London at 10 pounds
(Rs..650) a month to, 'see to it that my STD and ISD calls are billed to someone else.
YOU would not dare to speed beyond 55 mph (88 km/h) in Washington and then tell the traffic cop,
'Jaanta hai main kaun hoon (Do you know who I am?). I am so and so's son. Take your two bucks and
get lost.'
YOU wouldn't chuck an empty coconut shell anywhere other than the garbage pail on the beaches in
Australia and New Zealand ..
Why don't YOU spit Paan on the streets of Tokyo?
Why don't YOU use examination jockeys or buy fake certificates in Boston ???
We are still talking of the same YOU.
YOU who can respect and conform to a foreign system in other countries but cannot in your own.
YOU who will throw papers and cigarettes on the road the moment you touch Indian ground.
If you can be an involved and appreciative citizen in an alien country, Why cannot you be the same
here in India ?
In America every dog owner has to clean up after his pet has done the job. Same in Japan .. Will
the Indian citizen do that here?
We go to the polls to choose a government and after that forfeit all responsibility.
We sit back wanting to be pampered and expect the government to do everything for us whilst our
contribution is totally negative.
4. We expect the government to clean up but we are not going to stop chucking garbage all over the
place nor are we going to stop to pick a up a stray piece of paper and throw it in the bin.
We expect the railways to provide clean bathrooms but we are not going to learn the proper use of
bathrooms.
We want Indian Airlines and Air India to provide the best of food and toiletries but we are not going
to stop pilfering at the least opportunity.This applies even to the staff who is known not to pass on
the service to the public.
When it comes to burning social issues like those related to women, dowry, girl child! and others
what do we do?
We make loud drawing room protestations and continue to do the reverse at home.
OUR EXCUSE?
'It's the whole system which has to change, how will it matter if I alone forego my sons' rights to a
dowry.'
So who's going to change the system? What does a system consist of?
Very conveniently for us it consists of our neighbours, other households, other cities, other
communities and the government. But definitely not ME & YOU.
When it comes to us actually making a positive contribution to the system we lock ourselves along
with our families into a safe cocoon and look into the distance at countries far away and wait for a
Mr. CLEAN to come along & work miracles for us with a majestic sweep of his hand or we leave the
country and run away like lazy cowards hounded by our fears we run to America to bask in their
glory and praise their system. When New York becomes insecure we run to England. When England
experiences unemployment, we take the next flight out to the Gulf. When the Gulf is war struck, we
demand to be rescued and brought home by the Indian government.
Everybody is out to abuse and rape the country. Nobody thinks of feeding the system. Our
conscience is mortgaged to money. Dear Indians, The article is highly thought inductive, calls for a
great deal of introspection and pricks one's conscience too…..
I am echoing J. F. Kennedy's words to his fellow Americans to relate to Indians…..'
ASK WHAT WE CAN DO FOR INDIA AND DO WHAT HAS TO BE DONE TO MAKE INDIA WHAT AMERICA
AND OTHER WESTERN COUNTRIES ARE TODAY'
Lets do what India needs from us.